文献速递脊柱关节炎其他结缔组织病

合并炎症性肠病损害银屑病关节炎生物制剂应答并增加残留症状负担

Concomitant inflammatory bowel disease impairs biologic response and increases residual symptom burden in psoriatic arthritis.
PubMed 文献 · Semin Arthritis Rheum · 2025-10-06

该回顾性匹配队列研究纳入120例起始TNF抑制剂或抗IL-12/23治疗的银屑病关节炎患者(60例合并IBD,60例不合并IBD),比较6个月时MDA和DAPSA缓解/LDA达成率。合并IBD组6个月MDA达成率为32.1%、DAPSA缓解/LDA为50.0%,均低于不合并IBD组的58.3%和78.3%;IBD独立预测较低的MDA达成几率(aOR 0.28)。12个月时合并IBD组VAS疼痛、PtGA和HAQ-DI评分持续较高。

要点

  • 合并IBD的PsA患者6个月MDA达成率32.1%,低于不合并IBD者的58.3%(p=0.005)。
  • 合并IBD的PsA患者6个月DAPSA缓解/LDA达成率50.0%,低于不合并IBD者的78.3%(p=0.008)。
  • IBD独立预测较低的MDA达成几率(aOR 0.28,95%CI 0.11-0.69;p=0.006)。

核心结论

  • 合并IBD与PsA患者生物制剂治疗应答受损及更大的残留症状负担相关,提示该表型需要量身定制的治疗策略。

研究设计与样本

  • 回顾性匹配队列研究,纳入2011至2023年间起始TNF抑制剂或抗IL-12/23药物的PsA患者,按年龄、性别、病程和生物制剂类别匹配合并IBD组(PsA-IBD)与不合并IBD组(Only-PsA),各60例,共120例。

主要发现

  • 6个月时PsA-IBD组MDA达成率32.1% vs Only-PsA组58.3%(p=0.005),DAPSA缓解/LDA达成率50.0% vs 78.3%(p=0.008)。
  • IBD独立预测较低的MDA达成几率(aOR 0.28,95%CI 0.11-0.69;p=0.006),与DAPSA应答降低呈临界关联(aOR 0.39,95%CI 0.15-1.02;p=0.055)。
  • 12个月时PsA-IBD组报告持续较高的VAS疼痛、PtGA和HAQ-DI评分,尽管客观临床改善。

关键数值与推荐

  • 6个月MDA达成率:PsA-IBD组32.1% vs Only-PsA组58.3%(p=0.005)。
  • 6个月DAPSA缓解/LDA达成率:PsA-IBD组50.0% vs Only-PsA组78.3%(p=0.008)。
  • MDA的独立预测因素:IBD(aOR 0.28,95%CI 0.11-0.69;p=0.006)。
  • DAPSA应答的独立预测因素:IBD(aOR 0.39,95%CI 0.15-1.02;p=0.055)。

临床怎么用

  • 合并IBD的PsA患者起始TNF抑制剂或抗IL-12/23药物治疗时,6个月MDA和DAPSA缓解/LDA达成率较低。
  • 合并IBD的PsA患者12个月时VAS疼痛、PtGA和HAQ-DI评分持续较高,尽管客观临床改善。
  • 合并IBD是PsA患者6个月MDA达成率较低的独立预测因素。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the impact of concomitant inflammatory bowel disease (IBD) on clinical response to biologic therapy in psoriatic arthritis (PsA). The primary aim was to identify predictors of achieving minimal disease activity (MDA) and DAPSA remission or low disease activity (LDA) at 6 months. METHODS: We conducted a retrospective, matched cohort study of PsA patients initiating TNF inhibitors or anti-IL-12/23 agents between 2011 and 2023. Patients with (PsA-IBD) and without IBD (Only-PsA) were matched for age, sex, disease duration, and biologic class. Clinical assessments and patient-reported outcomes (PROs) were collected at baseline, 6, and 12 months. Multivariable logistic regression models were used to identify independent predictors of MDA and DAPSA remission/LDA at 6 months. Secondary outcomes included the proportion of patients achieving these targets over time and changes in disease activity scores and PROs. RESULTS: A total of 120 PsA patients (60 PsA-IBD and 60 Only-PsA) were analyzed. At 6 months, MDA and DAPSA remission/LDA were achieved by 32.1 % and 50.0 % of PsA-IBD patients vs. 58.3 % and 78.3 % of Only-PsA patients (p = 0.005 and p = 0.008). IBD independently predicted lower odds of MDA (aOR 0.28, 95 % CI 0.11-0.69; p = 0.006) and showed a borderline association with reduced DAPSA response (aOR 0.39, 95 % CI 0.15-1.02; p = 0.055). At 12 months, PsA-IBD patients reported persistently higher VAS pain, PtGA, and HAQ-DI scores despite objective clinical improvements. CONCLUSION: Concomitant IBD is associated with impaired treatment response and greater residual symptom burden in PsA, underscoring the need for tailored therapeutic strategies in this challenging phenotype.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Morrone M, Venerito V, Giannotta MG, et al. Concomitant inflammatory bowel disease impairs biologic response and increases residual symptom burden in psoriatic arthritis. Semin Arthritis Rheum. 2025. PMID: 41106092. doi:10.1016/j.semarthrit.2025.152848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。